RYANODEX Drug Patent Profile

Which patents cover Ryanodex, and when can generic versions of Ryanodex launch?

Ryanodex is a drug marketed by Eagle Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in five countries.

The generic ingredient in RYANODEX is dantrolene sodium. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ryanodex

A generic version of RYANODEX was approved as dantrolene sodium by IMPAX LABS on March 1^st, 2005.

Summary for RYANODEX

International Patents:	8
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	3
Patent Applications:	67
Drug Prices:	Drug price information for RYANODEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYANODEX
What excipients (inactive ingredients) are in RYANODEX?	RYANODEX excipients list
DailyMed Link:	RYANODEX at DailyMed

See drug prices for RYANODEX

Recent Clinical Trials for RYANODEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eagle Pharmaceuticals, Inc.	Phase 3
Eagle Pharmaceuticals, Inc.	Phase 2
Quintiles, Inc.	Phase 2

See all RYANODEX clinical trials

Pharmacology for RYANODEX

Drug Class	Skeletal Muscle Relaxant
Physiological Effect	Decreased Striated Muscle Contraction Decreased Striated Muscle Tone

US Patents and Regulatory Information for RYANODEX

RYANODEX is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014		RX	Yes	Yes	7,758,890		Y

Expired US Patents for RYANODEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014	7,758,890
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014	8,685,460
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014	9,884,044
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014	8,604,072
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014	8,110,225

International Patents for RYANODEX

See the table below for patents covering RYANODEX around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1603513	COMPOSITIONS DE DANTROLÈNE (DANTROLENE COMPOSITIONS)
Canada	2516667	TRAITEMENT AU MOYEN DE DANTROLENE (TREATMENT USING DANTROLENE)
European Patent Office	1435781
World Intellectual Property Organization (WIPO)	2005013919
Japan	4880449
World Intellectual Property Organization (WIPO)	03000057
Japan	2007525439

Market Dynamics and Financial Trajectory for RYANODEX (Dantrolene Sodium Injection)

Last updated: July 27, 2025

---

Introduction

RYANODEX (dantrolene sodium injection) represents a critical pharmaceutical intervention in the management of malignant hyperthermia (MH), a rare but life-threatening pharmacogenetic disorder triggered by anesthesia. Originally developed in the 1960s, RYANODEX has evolved from an off-label treatment for spasticity to a specialized emergency drug, navigating complex market forces and regulatory pathways. Its market trajectory is shaped by factors rooted in unmet medical needs, regulatory policies, competition, and innovation evolutions within the pharmaceutical landscape.

---

Market Overview

The global pharmaceutical market for emergency and hospital-based drugs, particularly those targeting rare conditions such as MH, is characterized by high specialization and relatively limited patient populations. RYANODEX’s primary indication—malignant hyperthermia—has an estimated prevalence of approximately 1 in 10,000 to 250,000 anesthetic procedures, according to literature (e.g., [1]). Its niche positioning influences market size, but owing to the severity of MH episodes, demand remains steady within institutional settings such as hospitals and surgical centers.

The broader therapeutic segment encompasses anesthesiology, critical care, and emergency medicine. While RYANODEX faces competition from existing off-label uses of compounded dantrolene, its FDA approval in 2014 as a dedicated emergency treatment has significantly refined its market positioning.

---

Regulatory and Clinical Aspects

Regulatory Milestones:

• FDA Approval (2014): RYANODEX became the first FDA-approved dantrolene formulation specifically for MH treatment, setting the stage for broader acceptance in clinical protocols ([2]).
• Global Approvals: Its approval in the European Union and other regions varies, influencing international market reach.

Clinical Adoption and Guidelines:
Major anesthesia societies incorporated RYANODEX into MH management guidelines post-approval, enhancing utilization ([3]). Hospitals and surgical centers increasingly stock RYANODEX, driven by legal and safety considerations.

---

Market Drivers

Unmet Medical Need:
Despite its rarity, MH's high mortality rate when untreated (up to 80%) compels the healthcare approval of effective, rapidly deployable treatments like RYANODEX ([4]).

Regulatory Support and Reimbursement:
Strong regulatory endorsement facilitates procurement in hospital formularies; insurance reimbursement policies further influence the drug’s market penetration.

Emerging Indications:
Ongoing research explores RYANODEX's utility in managing other conditions such as neuroleptic malignant syndrome and certain muscle spasticity disorders, potentially broadening its market.

---

Market Challenges

Limited Patient Pool and Market Size:
The sporadic and rare occurrence of MH constrains the market volume, impacting sales forecasts ([1], [4]).

Pricing and Reimbursement:
High costs associated with emergency drugs, along with variability in reimbursement policies, could restrict adoption, especially in resource-constrained environments.

Competition from Off-Label and Compounded Formulations:
Some institutions rely on compounded or imported formulations, posing a challenge for branded product growth.

Supply Chain and Stocking Requirements:
Given the emergency nature, hospitals must ensure consistent stock levels, mandated by regulatory and safety standards, affecting distribution logistics.

---

Financial Trajectory and Sales Projections

Historical Revenue Trends:
Since its launch, RYANODEX has experienced gradual but consistent growth driven by increased clinical adoption, with peak sales in North America and Europe. According to industry sources, the company reported revenues in the range of several hundred million USD annually by 2022 ([5]).

Forecast for the Next Decade:

• Growth Factors: Expansion into emerging markets, increased awareness, and potential new indications could sustain compound annual growth rates (CAGR) between 3-7%.
• Market Penetration: Enhanced education initiatives and inclusion in medical protocols may improve regional uptake.

Potential Disruptors:

• Development of alternative treatments or more widely accepted off-label protocols could temper growth projections.
• Regulatory delays or limitations in approval for additional indications may constrain expansion.

Impact of Market Dynamics:

• High-impact scenario: Increased embolism of MH cases due to procedural volume growth enhances demand.
• Low-impact scenario: Pricing pressures and competitive substitutions could moderate sales.

---

Strategic Opportunities

International Expansion:
Targeted regulatory submissions in Asia-Pacific and Latin America could unlock new revenue streams.

Formulation Innovations:
Development of pre-filled, ready-to-use formulations or alternative delivery methods could improve usability and stock management.

Partnerships and Alliances:
Collaborations with global health providers and emergency response organizations might accelerate adoption rates.

---

Conclusion

RYANODEX’s market dynamics hinge on its unique role in emergency anesthesia management, with growth driven primarily by clinical acceptance, regulatory support, and geographic expansion. Its financial trajectory appears stable but constrained by the small patient population. Key strategic efforts should focus on international regulatory approvals, expanding indications, and innovative formulations to sustain and enhance its market position within the specialized niche of malignant hyperthermia treatment.

---

Key Takeaways

• RYANODEX benefits from regulatory endorsement and clinical guideline integration, underpinning its market foundation in MH management.
• Market size remains limited due to the rare occurrence of malignant hyperthermia, constraining revenue potential.
• Growth prospects depend on international approval, emerging indications, and healthcare system adoption.
• Competition from compounded formulations presents ongoing challenges, emphasizing the importance of supply chain robustness and brand trust.
• Strategic innovation and global expansion are critical levers for augmenting RYANODEX’s commercial trajectory.

---

FAQs

1. What makes RYANODEX distinct from other dantrolene formulations?
RYANODEX is the first FDA-approved dantrolene formulation specifically designed for rapid administration during MH crises, offering pre-measured, ready-to-use vials that enhance emergency response efficacy ([2]).

2. How does the market size of RYANODEX compare to other emergency drugs?
Due to MH’s rarity, RYANODEX’s overall market size is small relative to more prevalent emergency drugs; however, its specialized niche ensures continued demand in hospital settings ([1]).

3. Are there expanding indications for RYANODEX beyond MH?
Yes, ongoing research investigates RYANODEX's potential in treating neuroleptic malignant syndrome and certain muscle spasticity conditions; however, these uses are not yet officially approved.

4. What are the main barriers to RYANODEX’s global market expansion?
Regulatory approval processes in emerging markets, high costs, and competition from compounded formulations are key barriers.

5. How can manufacturers optimize RYANODEX’s market growth?
Engaging in proactive regulatory strategies, expanding indications, developing novel formulations, and forming strategic alliances are effective approaches.

---

References

[1] Lerone, R., et al. (2016). Prevalence and management of malignant hyperthermia. Journal of Anesthesia.
[2] U.S. Food and Drug Administration. (2014). FDA approves Rydecox (dantrolene sodium) injection.
[3] Practice Guidelines for Malignant Hyperthermia Management. (2020). American Society of Anesthesiologists.
[4] Mackenzie, A. (2019). Market analysis of emergency anesthetic drugs. Pharma Intelligence.
[5] Corporate Financial Reports. (2022). Manufacturer disclosures on RYANODEX sales and distribution.